Enterprise mergers and acquisitions(M&A)are vital strategies for companies worldwide to expand markets,enhance competitiveness,and achieve strategic goals.The Chinese government’s strong support for the new energ...Enterprise mergers and acquisitions(M&A)are vital strategies for companies worldwide to expand markets,enhance competitiveness,and achieve strategic goals.The Chinese government’s strong support for the new energy industry has created a favorable policy environment for the development of the lithium battery sector.Against this backdrop,Tianqi Lithium Corp’s acquisition of Sociedad Química y Minera(SQM)in Chile has garnered widespread attention.This paper takes Tianqi Lithium Corp’s acquisition of SQM as the research subject,conducting a detailed analysis of the motives behind the M&A.Subsequently,financial indicators are employed to conduct a performance analysis from a financial perspective,examining the impact of the M&A.Finally,based on the findings of the case analysis,relevant suggestions are proposed to offer a reference for the development of enterprise mergers and acquisitions.展开更多
Background： The rapid growth of type 2 diabetes mellitus （T2DM） remains a big challenge for clinicians worldwide.Traditional Chinese medicine may bring a new approach for solving this problem. The Tianqi Capsule Di...Background： The rapid growth of type 2 diabetes mellitus （T2DM） remains a big challenge for clinicians worldwide.Traditional Chinese medicine may bring a new approach for solving this problem. The Tianqi Capsule DiabetesPrevention Study （REDUCES Study） reported that 1 years of therapy with Tianqi capsule reduced the risk of diabetes by32.1% compared with the placebo. Here we aimed to assess the long-term effect of Tianqi capsule on prevention ofT2DM in people with impaired glucose tolerance after discontinuation of active intervention. Methods/design： 420subjects will be followed-up for 8 years to assess the long-term effect of Tianqi capsule intervention. The causes of deathand the status of living subjects will be investigated. Follow-up data for living subjects will be collected by personalinterview and clinical examination and medical record review to determine diabetes status. Questionnaires will be givento all the subjects to investigate the factors that probably affect the diabetes status during the 8-year of discontinuation ofintervention. The primary outcome is the incidence of T2DM, and the secondary outcomes are body mass index, bloodglucose, blood lipids and blood pressure. The Cox proportional hazards model will be used to estimate the hazard ratiofor diabetes incidence. Analyses will be done with SAS 8.2 software package. Discussion： Results from this study mayprovide evidence for the long-term efficacy of Tianqi capsule in patients with prediabetes. The findings will provide abasis for further confirmatory studies. Ethics： The protocol has been approved by the Medical Ethics Committee ofGuang’anmen Hospital of China Academy of Chinese Medical Sciences （approval number 2016-046-KY-01）. Studyregistration number： ClinicalTrials.gov; NCT02848053.展开更多
Background Patients with Parkinson’s disease(PD)undergoing long-term levodopa therapy are prone to develop levodopa-induced dyskinesia(LID).Amantadine is the main drug recommended for the treatment of LID by current ...Background Patients with Parkinson’s disease(PD)undergoing long-term levodopa therapy are prone to develop levodopa-induced dyskinesia(LID).Amantadine is the main drug recommended for the treatment of LID by current guidelines,but it is far from meeting clinical needs.Tianqi Pingchan Granule(TPG),a compound Chinese herbal medicine,has been developed to relieve symptom of LID.Objective This randomized controlled trial evaluated the efficacy and safety of the combination of TPG and amantadine for LID.Design,setting,participants and interventions This is a randomized double-blind placebo-controlled trial,conducted from January 2020 to August 2021 at 6 sites in Jiangsu,Zhejiang and Shanghai,China.One hundred PD patients with≥0.5 h of LID were randomly assigned to either the TPG plus amantadine group(TPG group)or the placebo plus amantadine group(placebo group),and treated for a period of 12 weeks.To ensure unbiased results,all study participants,investigators and sponsors were unaware of group allocations.Additionally,the data analysts remained blinded until the analysis was finalized.Main outcome measures The primary outcome was assessed using the Unified Dyskinesia Rating Scale(UDysRS)(Range 0–104).The key secondary end point was improvement of motor and non-motor symptoms.Safety analyses included all enrolled patients.Results One hundred patients were enrolled and randomized into the two treatment groups.The changes in UDysRS at week 12 were–11.02 for the TPG group and–4.19 for the placebo group(treatment difference–6.83[–10.53 to–3.12];P=0.0004).Adverse events were reported for 2 of 50 patients(4.0%)in each of the groups.Conclusion This study indicated that a 12-week treatment of amantadine plus TPG effectively reduced UDysRS scores and was well tolerated,demonstrating the efficacy and safety of TPG for the treatment of LID in PD.展开更多
TianQi Lithium released its semi-annual performance report in 2019:The company achieved operating income of RMB 2589.54million,presenting a YOY decrease of 21.28%.Main reasons are:In January to June,2018,the price of ...TianQi Lithium released its semi-annual performance report in 2019:The company achieved operating income of RMB 2589.54million,presenting a YOY decrease of 21.28%.Main reasons are:In January to June,2018,the price of the company’s lithium chemical products was still at a high level.Since the second half of 20]&the adjustment in supply and demand pattern in this industry caused some restraints in the price of lithium chemical product,leading to obvious decrease in sales income in January to June,2019,compared with the same period in the previous year.During the report period,net profit attributable to shareholders in listed company was RMB 205.6176 million,presenting a YOY decrease of 84.30%.展开更多
According to eastmoney.com’s Choice data,50listed non-ferrous metals companies have announced the 2017 performance forecasts,where 39 companies forecast profits,accounting for more than 70%.Among them,there are 19 co...According to eastmoney.com’s Choice data,50listed non-ferrous metals companies have announced the 2017 performance forecasts,where 39 companies forecast profits,accounting for more than 70%.Among them,there are 19 companies each with a forecast net profit of more than RMB 100million and 13 companies with a more展开更多
目的:观察天芪降糖胶囊联合二甲双胍治疗老年2型糖尿病伴脑微血管病变的疗效和安全性。方法:96例老年2型糖尿病伴脑微血管病变患者随机分为对照组(48例)和观察组(48例)。对照组患者给予盐酸二甲双胍片0.5 g,口服,每日3次;观察组患者在...目的:观察天芪降糖胶囊联合二甲双胍治疗老年2型糖尿病伴脑微血管病变的疗效和安全性。方法:96例老年2型糖尿病伴脑微血管病变患者随机分为对照组(48例)和观察组(48例)。对照组患者给予盐酸二甲双胍片0.5 g,口服,每日3次;观察组患者在对照组治疗的基础上给予天芪降糖胶囊1.6 g,口服,每日3次。两组均用药4周。观察两组患者的临床疗效,治疗前后中医证候总积分、血糖水平[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)]、血脂水平[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]、超敏C反应蛋白(hs-CRP)和内皮素-1(ET-1)水平、血液流变学指标、氧化应激指标[丙二醛(MDA)、超氧化物歧化酶(SOD)]及不良反应发生情况。结果:观察组患者总有效率显著高于对照组(89.58%vs.70.83%),差异有统计学意义(P<0.05)。治疗后,两组患者中医证候总积分和血糖、hs-CRP、ET-1、TC、TG、LDL-C、血液流变学指标、MDA水平均显著低于同组治疗前,且观察组中医证候总积分、FPG、2 h PG、hs-CRP、ET-1、TC、TG、LDL-C、血液流变学指标、MDA水平均显著低于对照组;两组患者SOD水平均显著高于同组治疗前,且观察组显著高于对照组,同时观察组HDL-C水平显著高于同组治疗前及对照组,差异均有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:天芪降糖胶囊联合二甲双胍治疗老年2型糖尿病伴脑微血管病变的疗效显著,可降低血糖、血脂水平,改善机体血液流变学状态及氧化应激反应,且安全性较好。展开更多
文摘Enterprise mergers and acquisitions(M&A)are vital strategies for companies worldwide to expand markets,enhance competitiveness,and achieve strategic goals.The Chinese government’s strong support for the new energy industry has created a favorable policy environment for the development of the lithium battery sector.Against this backdrop,Tianqi Lithium Corp’s acquisition of Sociedad Química y Minera(SQM)in Chile has garnered widespread attention.This paper takes Tianqi Lithium Corp’s acquisition of SQM as the research subject,conducting a detailed analysis of the motives behind the M&A.Subsequently,financial indicators are employed to conduct a performance analysis from a financial perspective,examining the impact of the M&A.Finally,based on the findings of the case analysis,relevant suggestions are proposed to offer a reference for the development of enterprise mergers and acquisitions.
文摘Background： The rapid growth of type 2 diabetes mellitus （T2DM） remains a big challenge for clinicians worldwide.Traditional Chinese medicine may bring a new approach for solving this problem. The Tianqi Capsule DiabetesPrevention Study （REDUCES Study） reported that 1 years of therapy with Tianqi capsule reduced the risk of diabetes by32.1% compared with the placebo. Here we aimed to assess the long-term effect of Tianqi capsule on prevention ofT2DM in people with impaired glucose tolerance after discontinuation of active intervention. Methods/design： 420subjects will be followed-up for 8 years to assess the long-term effect of Tianqi capsule intervention. The causes of deathand the status of living subjects will be investigated. Follow-up data for living subjects will be collected by personalinterview and clinical examination and medical record review to determine diabetes status. Questionnaires will be givento all the subjects to investigate the factors that probably affect the diabetes status during the 8-year of discontinuation ofintervention. The primary outcome is the incidence of T2DM, and the secondary outcomes are body mass index, bloodglucose, blood lipids and blood pressure. The Cox proportional hazards model will be used to estimate the hazard ratiofor diabetes incidence. Analyses will be done with SAS 8.2 software package. Discussion： Results from this study mayprovide evidence for the long-term efficacy of Tianqi capsule in patients with prediabetes. The findings will provide abasis for further confirmatory studies. Ethics： The protocol has been approved by the Medical Ethics Committee ofGuang’anmen Hospital of China Academy of Chinese Medical Sciences （approval number 2016-046-KY-01）. Studyregistration number： ClinicalTrials.gov; NCT02848053.
基金supported by the National Key R&D Program of China(No.2017YFC1310300)National Natural Science Foundation of China(No.81974173,82171242)Pilot Project of Clinical Cooperation Between Chinese and Western Medicine in Shanghai(No.ZXYXZ-201907).
文摘Background Patients with Parkinson’s disease(PD)undergoing long-term levodopa therapy are prone to develop levodopa-induced dyskinesia(LID).Amantadine is the main drug recommended for the treatment of LID by current guidelines,but it is far from meeting clinical needs.Tianqi Pingchan Granule(TPG),a compound Chinese herbal medicine,has been developed to relieve symptom of LID.Objective This randomized controlled trial evaluated the efficacy and safety of the combination of TPG and amantadine for LID.Design,setting,participants and interventions This is a randomized double-blind placebo-controlled trial,conducted from January 2020 to August 2021 at 6 sites in Jiangsu,Zhejiang and Shanghai,China.One hundred PD patients with≥0.5 h of LID were randomly assigned to either the TPG plus amantadine group(TPG group)or the placebo plus amantadine group(placebo group),and treated for a period of 12 weeks.To ensure unbiased results,all study participants,investigators and sponsors were unaware of group allocations.Additionally,the data analysts remained blinded until the analysis was finalized.Main outcome measures The primary outcome was assessed using the Unified Dyskinesia Rating Scale(UDysRS)(Range 0–104).The key secondary end point was improvement of motor and non-motor symptoms.Safety analyses included all enrolled patients.Results One hundred patients were enrolled and randomized into the two treatment groups.The changes in UDysRS at week 12 were–11.02 for the TPG group and–4.19 for the placebo group(treatment difference–6.83[–10.53 to–3.12];P=0.0004).Adverse events were reported for 2 of 50 patients(4.0%)in each of the groups.Conclusion This study indicated that a 12-week treatment of amantadine plus TPG effectively reduced UDysRS scores and was well tolerated,demonstrating the efficacy and safety of TPG for the treatment of LID in PD.
文摘TianQi Lithium released its semi-annual performance report in 2019:The company achieved operating income of RMB 2589.54million,presenting a YOY decrease of 21.28%.Main reasons are:In January to June,2018,the price of the company’s lithium chemical products was still at a high level.Since the second half of 20]&the adjustment in supply and demand pattern in this industry caused some restraints in the price of lithium chemical product,leading to obvious decrease in sales income in January to June,2019,compared with the same period in the previous year.During the report period,net profit attributable to shareholders in listed company was RMB 205.6176 million,presenting a YOY decrease of 84.30%.
文摘According to eastmoney.com’s Choice data,50listed non-ferrous metals companies have announced the 2017 performance forecasts,where 39 companies forecast profits,accounting for more than 70%.Among them,there are 19 companies each with a forecast net profit of more than RMB 100million and 13 companies with a more
文摘目的:观察天芪降糖胶囊联合二甲双胍治疗老年2型糖尿病伴脑微血管病变的疗效和安全性。方法:96例老年2型糖尿病伴脑微血管病变患者随机分为对照组(48例)和观察组(48例)。对照组患者给予盐酸二甲双胍片0.5 g,口服,每日3次;观察组患者在对照组治疗的基础上给予天芪降糖胶囊1.6 g,口服,每日3次。两组均用药4周。观察两组患者的临床疗效,治疗前后中医证候总积分、血糖水平[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)]、血脂水平[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]、超敏C反应蛋白(hs-CRP)和内皮素-1(ET-1)水平、血液流变学指标、氧化应激指标[丙二醛(MDA)、超氧化物歧化酶(SOD)]及不良反应发生情况。结果:观察组患者总有效率显著高于对照组(89.58%vs.70.83%),差异有统计学意义(P<0.05)。治疗后,两组患者中医证候总积分和血糖、hs-CRP、ET-1、TC、TG、LDL-C、血液流变学指标、MDA水平均显著低于同组治疗前,且观察组中医证候总积分、FPG、2 h PG、hs-CRP、ET-1、TC、TG、LDL-C、血液流变学指标、MDA水平均显著低于对照组;两组患者SOD水平均显著高于同组治疗前,且观察组显著高于对照组,同时观察组HDL-C水平显著高于同组治疗前及对照组,差异均有统计学意义(P<0.05)。两组患者治疗期间均未见明显不良反应发生。结论:天芪降糖胶囊联合二甲双胍治疗老年2型糖尿病伴脑微血管病变的疗效显著,可降低血糖、血脂水平,改善机体血液流变学状态及氧化应激反应,且安全性较好。
